Benefits and safety of bimatoprost solution in small white patch on skin and comparison of its effect with that of tacrolimus
Not Applicable
- Conditions
- Health Condition 1: L80- Vitiligo
- Registration Number
- CTRI/2021/03/031699
- Lead Sponsor
- INDIRA GANDHI INSTITUTE OF MEDICAL SCIENCES
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with stable vitiligo(no progress of lesion and or development of new lesion during past 6 months)
Size of lesion should be less than 1% of body surface area
Less than or equal to 5 patches.
Patients on other treatment of vitiligo will be included only after wash out period of 1 week for topical and systemic drugs and 4 weeks for phototherapy
Exclusion Criteria
a)Patients with lesion more than 1% of body surface area
b) Number of lesion equal or more than 6
c)Periocular lesion
d)Active infections
e) Allergic reaction to Bimatoprost or /Tacrolimus
f)Pregnancy and lactation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method change of Vetiligo Extent Tensity Index(VETI) score from baseline over 3 monthsTimepoint: baseline (before administration of medicines) <br/ ><br>and every 4 weekly <br/ ><br>upto 3 months of starting of intervention.
- Secondary Outcome Measures
Name Time Method 1 change of vitiligo surface area from baseline over a peroid of 3 months <br/ ><br>2 Repigmentation grade after 3 months of intervention <br/ ><br>3 Repigmentation type after 3 months of intervention <br/ ><br>4 patient satisfaction by visual analog scale after intervention <br/ ><br>5 adverse events <br/ ><br>Timepoint: Base line then 4 weekly for 3 months